Influence of Quillaja saponaria triterpenoid content on the immunomodulatory capacity of Epstein-Barr virus iscoms

Scandinavian Journal of Immunology

Volumn 45, Issue 3, 1997, Pages 261-268

  Dotsika, E ^a   Karagouni, E ^a   Sundquist, B ^b   Morein, B ^c   Morgan, A ^d   Villacres Eriksson, M ^c  

^a HELLENIC PASTEUR INSTITUTE   (Greece)

^b NATIONAL VETERINARY INSTITUTE   (Sweden)

^c SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; ISCOM; QUIL A; TRITERPENOID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; H2 SYSTEM; IMMUNIZATION; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0031052744     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1997.d01-395.x     Document Type: Article

References (46)

1. Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben Efraim S, Gupta CK. Adjuvants - a balance between toxicity and adjuvanticity. Vaccine 1993;11:293-306.
2. Morein B, Sundquist B, Hogllund S. Iscom, a novel structure for antigenic presentation of membrane proteins from envelope viruses. Nature 1984;308:457-60.
3. Morein B, Lovgren K, Ronnberg B, Sjolander A, Villacres-Eriksson M. Immunostimulating complexes. Clinical potential in vaccine development. Clin Immunother 1995;3:461-75.
4. Kensil CR, Patel U, Lennick M, Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria molina cortex. J Immunol 1991;146:431-7.
5. Ronnberg B, Fekadu M, Morein B. Adjuvant activity of non toxic Quillaja saponaria molina components for use in iscom-matrix. Vaccine 1995;13:1375-82.
6. Behboudi S, Morein B, Ronnberg B. Isolation and quantification of Quillaja saponaria molina saponins and lipids in iscom-matrix and iscoms. Vaccine 1995;13:1690-6.
7. Thorley-Lawson DA, Poordy CA. Identification and isolation of the main component (gp340-gp220) Epstein-Barr virus responsible for generation neutralizing antibodies in vivo. J Virol 1982;43:730-6.
8. Hoffman GJ, Lazarowitz SG, Hayward SD. Monoclonal antibody against a 250 000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proc Natl Acad Sci USA 1980;77:2979-83.
9. + T-cell clones specific for the major envelope glycoprotein gp340. Eur J Immunol 1988;18:1689-97.
10. Cleary ML, Epstein MA, Finerty S et al. Individual tumours of multifocal EBV-induced malignant lymphomas in tamarins arise from different B-cell clones. Science 1985;228:722-4.
11. Morgan AJ. The development of Epstein-Barr virus vaccines. Vaccine 1992;10:563-71.
12. Morgan AJ. Development of Epstein-Barr Virus Vaccines, 1st edn. Heidelberg: Springer-Verlag, 1995.
13. Epstein MA, Morgan AJ, Finerty S, Randle BJ, Kirkwood JK. Protection of cottontop tamarins against Epstein-Barr virus induced malignant lymphoma by a prototype subunit vaccine. Nature 1985;318:287-9.
14. Morgan AJ, Allison AC, Finerty S, Scullion FT, Byars NE, Epstein MR. Validation of a first-generation Epstein-Barr virus vaccine preparation suitable for human use. J Med Virol 1989;29:74-8.
15. Morgan AJ, Mackett M, Finerty S, Arrand JR, Scullion FT, Epstein MA. Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas. J Med Virol 1988;25:189-95.
16. Ragot T, Finerty S, Watkins PE, Perricaudet M, Morgan AJ. Replication-defective recombinant adenovirus expressing the Epstein-Barr (EBV) glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the tamarin. J Gen Virol 1993;74:501-7.
17. Morgan AJ, Finerty S, Lovgren K, Scullion FT, Morein B. Prevention of Epstein-Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into immuno-stimulating complexes. J Gen Virol 1988;69:2093-6.
18. Bejarano MT, Masucci MG, Morgan A, Morein B, Klein G, Klein E. Epstein-Barr virus (EBV) antigens processed and presented by B cells, B blast and macrophages trigger T-cell mediated inhibition of EBV induced B cell transformation. J Virol 1990;64:1398-401.
19. Madej M, Conway MJ, Morgan AJ et al. Purification and characterization of Epstein-Barr virus gp340/220 produced by a bovine papilloma virus vector system. Vaccine 1992;10:777-82.
20. David EM, Morgan AJ. Efficient purification of Epstein-Barr virus membrane antigen gp340 by fast protein liquid chromatography. J Immunol Meth 1988;108:231-6.
21. Akerblom L, Nara P, Dunlop N, Putney S, Morein B. HIV experimental vaccines based on the iscom technology using envelope and gag gene products. Biotechnol Ther 1993;4:145-61.
22. de Schryver A, Klein G, Hewetson J et al. Comparison of EBV neutralization tests based on abortive infection of transformation of lymphoid cells and their relation to membrane reactive antibodies (anti MA). Int J Cancer 1974;13:353-62.
23. Lovgren-Bengtsson K, Sjolander A. Adjuvant activity of iscoms - effect of ratio and incorporation of antigen and adjuvant. Vaccine 1996;14:753-9.
24. Morein B, Lovgren K, Hoglund S, Sundquist B. The ISCOM: an immunostimulating complex. Immunol Today 1987;8:333-8.
25. Dalsgaard K. The application of the saponin adjuvant Quil A in foot-and-mouth disease vaccines. Bull Off Int Epiz 1978;89:963-6.
26. Mowat AM, Donachie AM. ISCOMS - a novel strategy for mucosal immunization? Immunol Today 1991;12:383-5.
27. Emini EA, Schleif WA, Silberklang M, Lehman D, Ellis RW. Vero cell-expressed Epstein-Barr (EBV) gp350/220 protects marmosets from EBV challenge. J Med Virol 1989;27:120-3.
28. Epstein MA, Randle BJ, Finerty S, Kirkwood JK. Not all potentially neutralizing vaccine-induced antibodies to Epstein-Barr virus ensure protection of susceptible experimental animals. Clin J Exp Immunol 1986;63:485-90.
29. Yao QY, Row M, Morgan AJ et al. Salivary and serum IgA antibodies to the Epstein-Barr virus glycoprotein gp340 and potential for virus neutralization. Inter J Cancer 1991;48:45-50.
30. Lovgren K, Kabery H, Morein B. An experimental influenza subunit vaccine (ISCOM)-induction of protective immunity to challenge infection in mice after intranasal or subcutaneous administration. Clin Exp Immunol 1990;82:435-9.
31. + T cell responses by oral or parenteral immunization with ISCOMS. Eur J Immunol 1995;25:2835-41.
32. Fossum C, Bergstrom M, Lovgren K, Watson DL, Morein B. Effect of iscoms and their adjuvant moiety (matrix) on the initial proliferation and IL-2 responses: comparison of spleen cells from mice inoculated with iscoms and/or matrix. Cell Immunol 1990;129:414-25.
33. Maloy KJ, Donachie AM, O'Hagan DT, Mowat AM. Induction of mucosal and systemic immune responses by immunization with ovalvumin entrapped in poly(lactide-co-glycolide) microparticles. Immunology 1994;81:661-7.
34. Karagouni EE, Hadjipetrou-Kourounakis L. Regulation of isotype immunoglobulin production by adjuvants in vivo. Scand J Immunol 1990;31:745-54.
35. Valensi J-P, Carlson JR, Van Nest GA. Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. J Immunol 1994;153:4029-39.
36. Villacres-Eriksson M, Bergstrom-Mollaoglu M, Kaberg H, Morein B. Involvement of interleukin-2 and interferon-gamma in the immune response induced by influenza virus iscoms. Scand J Immunol 1992;36:421-6.
37. Villacres-Eriksson M. Antigen presentation by naive macrophages, dendritic cells and B cells primed T lymphocytes and their cytokine production following exposure to immunostimulating complexes. Clin Exp Immunol 1995;102:46-52.
38. Bergstrom-Mollaoglu M, Lovgren K, Akerblom L, Fossum C, Morein B. Antigen-specific increases in the number of splenocytes expressing MHC class II molecules following restimulation with antigen in various physical forms. Scand J Immunol 1992;36:567-74.
39. + cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature 1990;344:873-5.
40. Zugel U, Schoel B, Yamamoto S, Hengel H, Morein B, Kaufmann SHE. Crossrecognition by CD8 T cell receptor αβ cytotoxic T lymphocytes of peptides in the self and the mycobacterial hsp60 which share intermediate sequence homology. Eur J Immunol 1995;25:451-8.
41. + T cells acquire specific lymphokine secretion potentials during thymic maturation. Nature 1991;353:68-70.
42. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996;17:138-46.
43. Golding B, Scott DE. Vaccine strategies: targeting helper T cell responses. Ann NY Acad Sci 1995;754:126-37.
44. Putkonen P, Bjorling E, Akerblom L et al. Long-standing protection of macaques against cell-free HIV-2 with a HIV-2 iscom vaccine. J AIDS 1994;7:551-9.
45. de Vries P, Heeney JL, Boes J et al. Protection of rhesus macaques from SIV infection by immunization with different experimental SIV vaccines. Vaccine 1994;15:1443-52.
46. Araujo FG, Morein B. Immunization with Trypanosoma cruzi epimastigote antigens incorporated into iscoms protects against lethal challenge in mice. Infect Immun 1991;59:2909-14.